Amgen Inc. (NASDAQ: AMGN) is scheduled to release its third-quarter financial results after the markets close on Thursday. Consensus estimates from Thomson Reuters call for $2.79 in earnings per share (EPS) and $5.73 billion in revenue. The third quarter of last year reportedly had EPS of $2.72 and $5.72 billion in revenue.
This biotech giant posted outstanding second-quarter earnings, and it remains a top stock for investors to buy. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, reaching millions of patients around the world and developing a pipeline of medicines with breakaway potential.
The company posted revenues above expectations and showed strong expense management in the previous quarter. It also raised guidance for revenues and earnings, and many on Wall Street think the numbers could be conservative. However, the caveat is that this stock has underperformed for the year, so buyer beware.
Many on Wall Street point to the company’s tremendous pipeline and outstanding forward earnings and revenue capabilities. Amgen’s double-digit earnings and revenue growth rate is expected to continue for the foreseeable future because of the company’s very deep clinical pipeline, which includes potential blockbusters Repatha for high cholesterol and Kyprolis for relapsed multiple myeloma. Amgen also has one of the industry’s deepest biosimilar pipelines, which is expected to generate upward of $3 billion in annual sales in the years ahead.
A few analysts weighed in on Amgen ahead of the earnings report:
- Jefferies reiterated a Buy rating.
- Citigroup has a Neutral rating with a $172 price target.
- JPMorgan reiterated a Hold rating.
- Goldman Sachs reiterated a Buy rating with a $206 price target.
- BMO Capital Markets reiterated an Outperform rating with a $190 price target.
- Leerink Swann reiterated a Hold rating.
- Credit Suisse has a Buy rating with a $206 price target.
- Piper Jaffray has a Buy rating with a $193 price target.
- Morgan Stanley reiterated an Overweight rating with a $198 price target.
Excluding Thursday’s move, Amgen has underperformed the broad markets with the stock down about 2% year to date. Over the past 52 weeks, the number is incredibly similar.
Shares of Amgen were trading up over 1% at $160.81 on Thursday, with a consensus analyst price target of $189.41 and a 52-week trading range of $139.02 to $176.85.
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.